ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature

• Published in: Cancer research (Chicago, Ill.) Vol. 62; no. 24; pp. 7247 - 7253
• Main Authors: DAVIS, Peter D, DOUGHERTY, Graeme J, HILL, Sally A, BLAKEY, David C, GALBRAITH, Susan M, TOZER, Gillian M, HOLDER, Angela L, NAYLOR, Matthew A, NOLAN, John, STRATFORD, Michael R. L, CHAPLIN, David J
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15.12.2002
• Subjects: Adenocarcinoma - blood supply; Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Angiogenesis Inhibitors - chemical synthesis; Angiogenesis Inhibitors - pharmacokinetics; Angiogenesis Inhibitors - pharmacology; Animals; Antineoplastic agents; Biological and medical sciences; Carcinoma, Squamous Cell - blood supply; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - pathology; Cattle; Cell Survival - drug effects; Chemotherapy; Colchicine - analogs & derivatives; Colchicine - pharmacology; Dose-Response Relationship, Drug; Endothelium, Vascular - cytology; Endothelium, Vascular - drug effects; Female; Humans; Mammary Neoplasms, Experimental - blood supply; Mammary Neoplasms, Experimental - drug therapy; Mammary Neoplasms, Experimental - pathology; Medical sciences; Mice; Mice, Inbred CBA; Mice, SCID; Necrosis; Neoplasms, Experimental - blood supply; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - pathology; Neovascularization, Pathologic - drug therapy; Organophosphorus Compounds - chemical synthesis; Organophosphorus Compounds - pharmacokinetics; Organophosphorus Compounds - pharmacology; Pharmacology. Drug treatments; Pharyngeal Neoplasms - blood supply; Pharyngeal Neoplasms - drug therapy; Pharyngeal Neoplasms - pathology; Prodrugs - chemical synthesis; Prodrugs - pharmacokinetics; Prodrugs - pharmacology; Protein Binding; Tubulin - metabolism; Xenograft Model Antitumor Assays; Antineoplastic agent; Human; Endothelial cell; Intraperitoneal administration; Rodentia; Prodrug; Malignant tumor; In vitro; Biological activity; In vivo; Vertebrata; Chemotherapy; Mammalia; Treatment; Mouse; Animal; Blood vessel; Established cell line; Antiangiogenic agent; Mechanism of action
• ISSN: 0008-5472; 1538-7445

Physiological differences between tumor and normal vasculature provide a target for drug discovery. In particular, the immature nature of tumor vasculature may render it intrinsically sensitive to disruption by agents affecting the endothelial cell cytoskeleton, including tubulin-binding agents. In this article, we report the synthesis of a water-soluble phosphate prodrug, ZD6126, of the tubulin-binding agent N-acetylcolchinol. In vitro studies demonstrate the comparative tubulin-binding properties of the prodrug and active drug, and show the induction of pronounced, reversible changes in endothelial cell morphology at subcytotoxic doses. Neither ZD6126 nor N-acetylcolchinol showed effects on the growth of human umbilical vein endothelial cells at concentrations below 100 micro M. In contrast, changes in endothelial cell morphology were seen at much lower, noncytotoxic concentrations (0.1 micro M) of ZD6126 and more pronounced effects were seen in proliferating versus confluent endothelial cell cultures. In vivo studies were carried out using a murine tumor model (CaNT) with single administration of a dose well below the maximum tolerated dose. These studies showed a large reduction in vascular volume, induction of extensive necrosis in tumors, and a reduced tumor cell yield in a clonal excision assay, consistent with vascular rather than cytotoxic effects. A viable rim of tumor remained after single-dose administration and minimal growth delay was observed. However, well-tolerated, multiple administration regimens led to pronounced tumor-growth delay. In the human xenograft FaDu, the growth delay given by a single dose of paclitaxel was enhanced by combination with a single dose of ZD6126, and the growth delay given by the combination was greater than the sum of the growth delays from the individual treatments. These findings show that ZD6126 is a promising antivascular agent for the treatment of solid tumors.